Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2016

Description:

Summary

‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2016’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- The report reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics and enlists all their major and minor projects
- The report assesses Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview
Therapeutics Development
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Overview
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics under Development by Companies
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics under Investigation by Universities/Institutes
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Products under Development by Companies
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Products under Investigation by Universities/Institutes
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Companies Involved in Therapeutics Development
ArQule, Inc.
EnGeneIC Ltd
Merck KGaA
Orphagen Pharmaceuticals, Inc.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles

ARQ-087 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ATR-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

avelumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TargomiRs - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Recent Pipeline Updates

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Product Development Milestones

Featured News & Press Releases
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016

Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015

Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers

Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2016

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by ArQule, Inc., H1 2016

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by EnGeneIC Ltd, H1 2016

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Merck KGaA, H1 2016

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Recent Pipeline Updates, H1 2016
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Dormant Projects, H1 2016
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2016
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3720439/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3720439/
Office Code: SCD2STRP

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp